Pfizer (PFE) Tops Q1 EPS by 2c, Lowers FY Guidance Due to Exchange Rates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
PFIZER REPORTS FIRST-QUARTER 2015 RESULTS
April 28, 2015 7:00 AM EDTFirst-Quarter 2015 Reported Revenues(1) of $10.9 Billion First-Quarter 2015 Adjusted Diluted EPS(2) of $0.51, Reported Diluted EPS(1) of $0.38; Both Adjusted Diluted EPS(2) and Reported Diluted EPS(1) Include a $0.03 Negative Impact Associated with an Upfront Payment to OPKO Health, Inc. (OPKO) Repurchased $6.0 Billion of Common Stock in First-Quarter 2015, Including a $5.0 Billion Accelerated Share Repurchase Agreement Executed in February Updated Certain Components of 2015 Financial Guidance Solely to Reflect the Negative Impact of Recent Changes in Foreign Exchange Rates
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:... More
